1035373-85-3Relevant articles and documents
BODIPY protein misfolding probe Hal-BODIPY, preparation method and application thereof
-
, (2021/01/29)
The invention discloses a BODIPY protein misfolding probe Halo-BODIPY, a preparation method and application thereof, wherein the structural formula of the fluorescent probe is shown as a formula I inthe specification. According to the invention, the micro
FLUORESCENCE DYE
-
, (2020/07/07)
The present invention relates to compound according to formulas (1), (15), (16) or (17), the use of the compounds as a fluorescent dye, and a fluorescent dye comprising the compounds. The invention also relates to a method for fluorescence-based identific
DYES FOR ANALYSIS OF SOLUBLE PROTEIN AGGREGATES OR MISFOLDED PROTEIN OLIGOMERS
-
Paragraph 0099; 00103, (2019/10/01)
Dye and compositions to monitor the multistep protein aggregation process in both test tubes and live cells are provided. These dyes can detect misfolded protein oligomers and distinguish insoluble protein aggregates from misfolded oligomers. Applications of these dyes include measuring kinetics of protein aggregation, monitoring aggregation of specific proteins in intact live cells, monitoring aggregation of cellular proteome in intact live cells, and tracking the time course of protein aggregation in cells under stress conditions.
Orientation-controlled conjugation of haloalkane dehalogenase fused homing peptides to multifunctional nanoparticles for the specific recognition of cancer cells
Mazzucchelli, Serena,Colombo, Miriam,Verderio, Paolo,Rozek, Ewa,Andreata, Francesco,Galbiati, Elisabetta,Tortora, Paolo,Corsi, Fabio,Prosperi, Davide
supporting information, p. 3121 - 3125 (2013/04/10)
In control: The ligand positioning and orientation on multifunctional nanoparticles (MNP) are controlled by using a versatile bimodular approach that exploits an 11 amino acid (U11) homing peptide genetically fused with a haloalkane dehalogenase (HALO) enzyme. The resultant nanoparticles have good targeting efficiency and selectivity toward broadly occurring urokinase plasminogen activator receptor positive human cancer cells.